FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming ...

FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and ...

As Cytek Biosciences navigates its regulatory quiet period, the investment community is looking ahead to the imminent release of its complete fourth-quarter and full-year 2025 financial results.

Cytek Biosciences, Inc. ((CTKB)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call of Cytek Biosciences, Inc. presented a mixed sentiment, reflecting ...

Interested parties may access live and archived webcasts of the presentations for the Stephens and Piper Sandler events referenced above on the “Investors” section of the company website at: investors ...

Cytek Biosciences has reported relatively small net losses, indicating that its financial position has not deteriorated significantly. In Q2 2025, the company had liquid assets of $262.02 million.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cytek Biosciences, Inc. before investing. In this article, we go over a few key ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the ...